Paolo Manca, Margherita Ambrosini, Alessandra Raimondi, Michele Prisciandaro, Floriana Nappo, Stefano Tamberi, Lorenzo Fornaro, Elisa Giommoni, Andrea Spallanzani, Samantha Di Donato, Ferdinando De Vita, Alessandro Bittoni, Antonia Strippoli, Giovanni Pennoni, Smruthy Sivakumar, Alexa Betzig Schrock, Sabina Murgioni, Sara Lonardi, Filippo Pietrantonio, Giovanni Randon. "Impact of molecular profile on switch maintenance to paclitaxel plus ramucirumab (PTX-RAM) versus continuation of first-line fluoropyrimidine and oxaliplatin (FOX) chemotherapy (ChT) in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: An exploratory endpoint of the ARMANI phase 3 randomized trial.." Journal of Clinical Oncology, 2026. doi:10.1200/jco.2026.44.16_suppl.4060